2013
Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides
Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. Journal Of The American Academy Of Dermatology 2013, 69: 537-543. PMID: 23849563, DOI: 10.1016/j.jaad.2013.04.063.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultAge FactorsAgedAnalysis of VarianceCohort StudiesDermatomycosesDose Fractionation, RadiationDose-Response Relationship, RadiationElectronsFemaleHumansIncidenceMaleMiddle AgedMultivariate AnalysisMycosis FungoidesNeoplasm InvasivenessNeoplasm StagingPrognosisRadiodermatitisRadiotherapy DosageRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex FactorsSkin Diseases, BacterialSkin NeoplasmsWhole-Body IrradiationConceptsTotal skin electron beam therapyMycosis fungoidesSkin infectionsElectron beam therapyAcute toxicityBeam therapyAcute treatment toxicityRetrospective study designIncidence of infectionRisk of infectionCommon toxicitiesTreatment toxicityCutaneous infectionsSkin painBaseline incidenceToxicity gradeGrade 3Modern seriesGrade 2Grade 1Consecutive coursesFungoidesInfectionStudy designGrade 4
2012
Pralatrexate: treatment of T-cell non-Hodgkins lymphoma
Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkins lymphoma. Future Oncology 2012, 9: 21-29. PMID: 23252560, DOI: 10.2217/fon.12.168.Peer-Reviewed Original ResearchConceptsRefractory peripheral T-cell lymphomaPeripheral T-cell lymphomaT-cell non-Hodgkin lymphomaVitamin B12 supplementationOverall response rateNon-Hodgkin lymphomaT-cell lymphomaPROPEL trialCommon toxicitiesB12 supplementationPatient populationClinical studiesResponse ratePralatrexateUS FDALymphomaMetabolic inhibitorsTreatmentToxicityNauseaThrombocytopeniaDoseTrialsSupplementationWeeks
2010
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Management And Research 2010, Volume 2: 53-59. PMID: 21188096, PMCID: PMC3004568, DOI: 10.2147/cmar.s5009.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaRecurrent cutaneous T-cell lymphomaTreatment of patientsT-cell lymphomaDenileukin diftitoxFusion protein toxinsT cellsCytocidal agentsRare lymphoproliferative disorderPivotal clinical trialsMalignant T cellsBiological response modifiersQuality of lifeMechanism of actionCD25 subunitCommon toxicitiesProgressive lymphomaLymphoproliferative disordersClinical trialsResponse modifiersIL2 receptorTraditional chemotherapyDiftitoxB cellsFDA approval